Our technology platform called Viaskin®, is based on an electrostatic patch, which administers the allergen directly on the skin.
A novel approach to immunotherapy
the allergen is concentrated in the superficial layers of the skin, where it
activates the immune system by specifically targeting antigen-presenting cells
without passage of the antigen into the bloodstream.
DBV calls this novel approach to immunotherapy as epicutaneous immunotherapy, or EPIT®.
DBV Technologies believes EPIT® has the potential to provide all of the intended benefits of a disease-modifying treatment in allergy, while avoiding severe or life-threatening allergic reactions.